ClinicalTrials.gg
RecruitingNCT07818811Updated Nov 18, 2026

Muscle Oxygenation and Function in Breast Cancer Survivors

An observational study in Breast Cancer Survivors, sponsored by Pamukkale University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Pamukkale University · Observational

Updated Nov 18, 2026Now RecruitingFirst site in Turkey (Türkiye)+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
80
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 399 studies in Breast Neoplasms with a site in Turkey — 83 open to participants now, 129 under way, 46 of them phase 3. Breast Neoplasms · Turkey.

Planned enrollment
40th of 79
80 · median 80
Started
2026
with 39 others
Observational
79 of 399
15 open now
Primary completion
2027-08
later than 101 of 128 live
Registered
390th of 399
by date

Among the 399 studies in Breast Neoplasms with a site in Turkey, this one is the 40th largest by planned enrollment of the 79 observational ones that give a count, is one of 40 that started in 2026, is one of 79 observational ones, reaches primary completion later than 101 of the 128 other live ones, and was the 390th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

83 of the 399 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 399 studies in Breast Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

Persistent impairments in upper extremity function are well documented among breast cancer survivors even after completion of cancer treatment. These impairments are frequently attributed to fatigue and other treatment-related complications. Upper extremity function in patients undergoing breast cancer surgery may be affected by multiple factors, including surgical tissue trauma, axillary lymph node dissection or sentinel lymph node biopsy, radiation-induced fibrosis, pain, restricted shoulder range of motion, loss of muscle strength, and lymphedema. Muscle oxygenation may also be impaired through various mechanisms following breast cancer surgery and is considered one of the important microvascular mechanisms potentially underlying upper extremity functional impairments. However, muscle oxygenation has not been sufficiently investigated in this population. Existing studies have predominantly focused on lower extremity muscles, whereas changes in upper extremity muscle oxygenation have yet to be adequately investigated. This gap in the literature may limit the development and targeted implementation of appropriate exercise interventions and the identification of optimal exercise modalities aimed at improving upper extremity function in daily life, enhancing independence, facilitating participation in social and occupational activities, and ultimately improving quality of life among breast cancer survivors.

In this project, the investigators aim to investigate the relationship between tissue-level muscle oxygenation parameters and clinical measures of upper extremity function, including muscle strength, upper extremity functional capacity, and the score on the Disabilities of the Arm, Shoulder and Hand Questionnaire-Quick Version (QuickDASH). By examining these associations, the investigators intend to contribute to a better understanding of the pathophysiological mechanisms underlying functional impairments in breast cancer survivors and to provide a basis for the development of more effective and targeted rehabilitation protocols, including interventions designed to enhance microcirculation and aerobic exercise capacity.

Breast cancer survivors followed at the Breast Clinic of the Department of General Surgery at Pamukkale University and healthy individuals will be included in two study groups. Upper extremity muscle oxygenation and functional performance will be assessed using a hand-held dynamometer, near-infrared spectroscopy (NIRS), the six-minute pegboard and ring test, and the Disabilities of the Arm, Shoulder and Hand Questionnaire-Quick Version (QuickDASH).

By comparing upper extremity muscle oxygenation and functional performance between breast cancer survivors and healthy individuals, the findings of this project are expected to provide a better understanding of the muscle characteristics underlying upper extremity functional impairments in breast cancer survivors. These findings may contribute to the development and refinement of exercise interventions within rehabilitation programs and highlight the importance of selecting appropriate exercise modalities to improve upper extremity function in this population.

03

Conditions studied

  • Breast Cancer Survivors

Browse trials for

Keywords

  • breast cancer survivors
  • muscle oxygenation
  • Upper extremity function
  • upper limb in breast cancer survivors
  • near-infrared spectroscopy
  • functional performance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

breast cancer survivors: At least 40 cases of patients aged 18 and older who met the inclusion criteria, who had undergone breast surgery (at least 6 months to a maximum of 15 years had elapsed since mastectomy and curative treatment), and who were being followed up at the General Surgery Breast Clinic of Pamukkale University healty individuals: At least 40 healthy individuals who are undergoing routine follow-up at the General Surgery Breast Clinic of Pamukkale University, have no history of cancer, and meet the criteria for inclusion in the control group

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals diagnosed with stage 1, 2, or 3 unilateral breast cancer
  • who completed breast cancer treatment at least 6 months ago
  • whose clinical condition is stable

Exclusion criteria

Exclusion Criteria:

  • having an upper extremity disability or musculoskeletal disorder that could affect physical performance
  • having undergone bilateral breast surgery
  • development of recurrence or
  • uncontrolled chronic cardiopulmonary diseases (hypertension, heart failure, peripheral artery disease, , asthma, etc.), uncontrolled chronic conditions such as diabetes or neuromotor disorders, anemia, smoking, or cognitive impairment
  • having participated in a regular exercise program within the last 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Breast cancer survivors

    At least 40 cases of patients aged 18 and older who met the inclusion criteria, who had undergone breast surgery (at least 6 months to a maximum of 15 years had passed since mastectomy and curative treatment), and who were being followed up at the General Surgery Breast Clinic of Pamukkale University

  • Healthy individuals

    At least 40 healthy individuals who are undergoing routine follow-up at the General Surgery Breast Clinic of Pamukkale University, have no history of cancer, and meet the criteria for inclusion in the control group

06

What researchers measure

Primary outcomes

  1. Muscle oxygenation will be assessed a noninvasive technique, using near-infrared spectroscopy (NIRS). NIRS can measure local muscle oxygen saturation (SmO₂) in the capillary bed of the underlying muscle tissue.

    The NIRS sensor will be secured using a fiber-elastic band over the midline of the lateral deltoid muscle, immediately inferior to the acromion. Physiological variables, including the minimum, maximum, and change values of muscle oxygen saturation, will be recorded at rest and during and after the Six-Minute Pegboard and Ring Test. Muscle oxygenation will be expressed as the percentage of oxyhemoglobin relative to the sum of oxyhemoglobin and deoxyhemoglobin. Bilateral musce oxygenation of the middle portion of the deltoid muscle will be assessed before, during, and after the test. During exercise, an inability to adequately meet the increased oxygen demand of the working muscle may result in reduced SmO₂ levels. SmO₂ is influenced by shifts in the hemoglobin dissociation curve as well as by other chemical and neural factors.

    Time frame: october 2026 to august 2027

Secondary outcomes

  1. upper extremity muscle strength

    The strength of the middle and anterior portions of the deltoid muscle will be assessed using a hand-held dynamometer. The test will be performed with the participant in an unsupported sitting position, with the shoulder positioned at 90° of abduction and 90° of flexion, in neutral rotation, and with the elbow fully extended. Resistance will be applied using the dynamometer over the distal humerus, and the participant will be instructed to attempt to elevate the arm with maximal force. Three measurements will be obtained, and the highest value will be recorded in Newtons (N).

    Time frame: october 2026 to august 2027

Other outcomes

  1. Functional performance of upper extremity

    Upper extremity functional exercise capacity will be assessed using the Six-Minute Pegboard and Ring Test. Participants will sit on an adjustable chair in front of a pegboard consisting of two lower horizontal bars positioned at shoulder height and shoulder width, one on the right and one on the left, and two upper bars positioned 20 cm above the lower bars. Each upper bar will contain 10 rings. Participants will be instructed to transfer the rings from the lower bars to the upper bars and then back to the lower bars as quickly as possible, using both arms simultaneously. If a participant requires rest, they will be permitted to rest while the test duration continues, with instructions to resume the test as soon as possible. The number of rings transferred during the 6-minute test will be recorded. Two rings removed and placed simultaneously will be counted as two rings.Blood pressure, heart rate, and peripheral oxygen saturation will be recorded before and immediately after the test.

    Time frame: october 2026 to august 2027

  2. upper extremity disability

    Upper extremity disability will be assessed using the Disabilities of the Arm, Shoulder and Hand Questionnaire-Quick Version (QuickDASH). The Turkish version of the QuickDASH, which has been demonstrated to be valid and reliable, will be used. The QuickDASH consists of 11 items, with each item scored on a 5-point scale ranging from 1 to 5 (1 = no difficulty, 2 = mild difficulty, 3 = moderate difficulty, 4 = severe difficulty, and 5 = unable to perform). The questionnaire assesses pain severity, activity-related pain, tingling, weakness, stiffness, difficulty performing physical activities due to upper extremity problems, and the impact of upper extremity problems on social activities, work, and sleep. The QuickDASH score ranges from 0 to 100, with higher scores indicating greater disability (0 = no disability; 100 = maximum disability). A score of ≥20 indicates clinically significant functional impairment.

    Time frame: october 2026 to august 2027

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There are currently no plans to share individual participant data with other researchers. Study results will be reported only in aggregated form, and no personally identifiable information will be disclosed.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Aug 2027, 9 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2026
First posted
Sep 14, 2026
StartActual
Nov 10, 2026was Oct 2026
Primary completionEst.
Aug 2027
CompletionEst.
Nov 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Pamukkale University · Denizli, Turkey (Türkiye)
Nov 18, 2026
Start date
Oct 2026→Nov 10, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Pamukkale University · Denizli, Turkey (Türkiye)
    Start date Oct 2026→Nov 10, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07818811
Responsible party
ATİYE KAŞ ÖZDEMİR (Lecturer PHd, Pamukkale University) — Principal investigator
First posted
Sep 14, 2026
Start date
Nov 10, 2026
Primary completion
Aug 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Atiye KAŞ ÖZDEMİR, Lecturer PhD
Contact
akas@pau.edu.tr
+905364720293
Atiye KAŞ ÖZDEMİR, Lecturer, PhD.
principal investigator · Pamukkale University
Sevda YILMAZ, Assoc. Prof. Dr.
study chair · Pamukkale University
Orçin TELLİ ATALAY, Prof. Dr.
study chair · Pamukkale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion